Global cancer therapy markets projected to grow significantly by 2030

Global markets for specialized cancer therapies are projected to see significant growth through 2030. According to reports from The Business Research Company, the gamma delta T cell cancer therapy market is expected to reach $4.94 billion by 2030, growing at a compound annual growth rate (CAGR) of 18.4%. This expansion is driven by increased clinical trials, advancements in next-generation T-cell engager (TCE) platforms, and the integration of artificial intelligence in patient monitoring.

Simultaneously, the thyroid cancer drug market is forecasted to reach $2.39 billion by 2030, with a projected CAGR of 12.8%. Growth in this sector is fueled by rising incidence and diagnosis rates, as well as the development of precision treatments. Notable industry developments include Eli Lilly and Company receiving FDA approval for selpercatinib to treat certain advanced thyroid cancers, and a partnership between Sanofi and Orano Med to develop next-generation radioligand therapies for rare cancers.

While North America currently holds the largest market share for both sectors, the Asia-Pacific region is expected to see the highest growth rate for gamma delta T cell therapies, while the Middle East is projected to lead in growth for thyroid cancer treatments.